Does Rallies show 13F holders for LPCN?

Yes. Rallies tracks hedge fund and 13F ownership data for LPCN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is LPCN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LPCN. It does not provide personalized investment advice.

LPCN (Lipocine Inc.) Stock Analysis - Hedge Fund Holdings

Lipocine Inc. (LPCN) is a publicly traded Healthcare sector company. As of May 21, 2026, LPCN trades at $2.24 with a market cap of $18.22M and a P/E ratio of 0.00. LPCN moved +2.27% today. Year to date, LPCN is -69.32%; over the trailing twelve months it is -38.46%. Its 52-week range spans $1.81 to $12.37. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces LPCN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LPCN stock?

Hedge funds tracked by Rallies that own LPCN include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lipocine Inc..

LPCN Key Metrics

Key financial metrics for LPCN
Metric	Value
Price	$2.24
Market Cap	$18.22M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$12.37
52-Week Low	$1.81
Volume	35
Avg Volume	0
Revenue (TTM)	$2.00M
Net Income	$-11.43M
Gross Margin	0.00%

Top Hedge Funds Holding LPCN

Renaissance Technologies holds 36.03K shares of LPCN, changed -10.66% as of Dec 31, 2024.
Two Sigma holds 12.82K shares of LPCN, changed -50.15% as of Jun 30, 2024.

Latest LPCN News

Lipocine Phase 3 PPD Trial Fails; Q1 Net Loss of $0.52/Share — May 7, 2026
Lipocine’s Oral Brexanolone Fails Phase 3 Endpoint, Shows −7.2 HAM-D Gains — Apr 2, 2026
Lipocine Reports $9.6M 2025 Loss, $14.9M Cash, April LPCN 1154 Data — Mar 10, 2026

Recent LPCN Insider Trades

Higuchi John W. bought 40.00K (~$81.20K) on Apr 7, 2026.
Higuchi John W. bought 123.00K (~$252.15K) on Apr 6, 2026.
Patel Mahesh V. bought 25.00K (~$50.75K) on Apr 6, 2026.

LPCN Analyst Consensus

2 analysts cover LPCN: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.

Common questions about LPCN

Who owns LPCN stock?: Hedge funds tracked by Rallies that own LPCN include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lipocine Inc..
Does Rallies show 13F holders for LPCN?: Yes. Rallies tracks hedge fund and 13F ownership data for LPCN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LPCN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LPCN. It does not provide personalized investment advice.